CD274 and neoplasm: An interesting study was held to find out whether the use of circulating tumor DNA (ctDNA) may influence the effect of durvalumab [64] and the results show that changes in somatic mutations in ctDNA are correlated with this anti-PD-L1 form of therapy and may be a good predictor of a successful immunotherapy.